Avidity Partners, an investment management firm that offers financial services, led a $50.7m Series D round in Quanta Therapeutics, a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes, with participation from Sofinnova Investments, Vida Ventures, Surveyor Capital, Longitude Capital, BVF Partners, AbbVie Ventures, GC&H Investments, and Wilson Sonsini. “We are pleased to add Avidity Partners to our strong syndicate of high quality investors that share our vision for developing next-generation oral KRAS inhibitors with the potential to address mutations beyond G12C. With this additional funding, we will be well positioned to rapidly advance our two lead KRAS programs into the clinic in 2024 and generate proof-of-concept data,” Perry Nisen, Quanta Therapeutics CEO.